The effectiveness of the long-term administration of therapeutic agents used for idiopathic short stature (ISS), such as recombinant human growth hormone (rhGH), aromatase inhibitors, metformin, and insulin-like growth factor-1 (IGF-1), remains a topic of controversy. This evidence concerns the gene CYP19A1 and SHOX-related short stature.